Multicenter Study Evaluating Thermal Ablation with Antithyroid Drugs for Primary Hyperthyroidism Treatment

What this Trial Is About

Hyperthyroidism is a condition caused by excessive thyroid hormone production, leading to increased metabolism and symptoms like weight loss, palpitations, and sweating. Traditional treatments include antithyroid drugs, radioactive iodine, and surgery, but each has limitations such as side effects, risk of recurrence, or complications. This research aims to evaluate the combined use of thermal ablation with antithyroid drugs as a promising approach to improve symptom control and long-term management in patients with primary hyperthyroidism. The study focuses on a combined treatment involving minimally invasive thermal ablation methods like radiofrequency or microwave ablation guided by ultrasound, alongside antithyroid drug therapy. Thermal ablation precisely destroys overactive thyroid tissue under local anesthesia, potentially reducing drug dosage and duration needed. This approach is intended to offer rapid symptom improvement with fewer side effects, minimal scarring, and cost advantages. The study will collect data from multiple centers to assess the effectiveness, safety, and factors influencing outcomes of this combined treatment. Participants will be monitored for up to three years, with evaluations including disease remission rates, thyroid volume changes, antibody levels, complication rates, and medication doses. Follow-up assessments will also track ablation volume ratio one month after treatment. The study involves informed consent and requires patients to have controlled heart rates and stable metabolic rates. Researchers aim to provide high-quality evidence to optimize therapy protocols and guide clinical use of this combined treatment strategy.

Efficacy of Thermal Ablation Combined With Antithyroid Drugs in the Treatment of Primary Hyperthyroidism